PIPELINE OVERVIEW

Aptose Biosciences is a clinical-stage biotechnology company with two active clinical programs, and a third program in the preclinical stage partnered with Ohm Oncology. Aptose’s oral CG-806 pan-FLT3 / pan-BTK inhibitor is currently in a Phase 1a/1b clinical trial for the treatment of patients with CLL and NHL, and is also being advanced towards an additional Phase 1a/1b trial in patients with AML and MDS. Aptose’s MYC inhibitor, APTO-253, is currently in a Phase 1b clinical trial for the treatment of patients with relapsed/refractory AML and high-risk MDS.